ClinicalTrials.gg
CompletedNCT06712836VESPER-1Updated Aug 28, 2026Results posted

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

A Phase 2 interventional study of MET097 and Placebo in Obesity and Overweight or Obesity, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.

Enrollment
12th of 21
239 · median 258
Started
2024
with 1 other
Phase 2
3 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
20 of 21
Pfizer

Among the 21 studies testing berobenatide in Obesity, this one is the 12th largest by enrollment, is one of 2 that started in 2024, is one of 3 in phase 2, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About berobenatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing berobenatide in Obesity, or all of them as a file.
02

Study summary

This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four different dose levels. Participants who have completed the first 28 weeks may participate in an exploratory extension study.

Read the detailed description

This is a multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of four different dose levels of MET097 vs. placebo for body weight loss in adult participants with obesity or overweight (body mass index [BMI] 27 to 50 kg/m2, aged 18 to 70), after 28 weeks with once weekly dosing. Participants who have completed the first 28 weeks may participate in an exploratory extension study that includes less frequent dosing regimens. After the dosing period, there is an additional post-treatment follow-up period.

03

Conditions studied

  • Obesity
  • Overweight or Obesity

Keywords

  • Overweight
  • GLP-1
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) at Screening of:

    • BMI ≥30 kg/m2 and ≤50.0 kg/m2 (can have the weight-related co-morbidities listed below)
    • BMI ≥27.0 kg/m2 to \<30.0 kg/m2 with at least one of the following weight-related co-morbidities:

      1. Hypertension: on blood pressure (BP)-lowering medication or having systolic BP ≥130 mmHg or diastolic BP ≥80 mmHg at Screening
      2. Dyslipidemia: on lipid-lowering medication or having low-density lipoprotein cholesterol (LDL-C) ≥160 mg/dL (4.1 mmol/L) or triglycerides ≥150 mg/dL (1.7 mmol/L), or high-density lipoprotein-cholesterol (HDL-C) \<40 mg/dL (1.0 mmol/L) for men or HDL-C \<50 mg/dL (1.3 mmol/L) for women at Screening

Stable body weight (increase or decrease ≤5 kg) within 3 months prior to Screening

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of diabetes (T1DM or T2DM) or A1c (HbA1c) ≥ 6.5% or fasting plasma glucose >125 mg/dL.
  • Estimated (eGFR) \<75 mL/min/1.73 m2
  • History of pancreatitis
  • Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
  • Any lifetime history of a suicide attempt.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    MET097 Active

    MET097 will be administered at four different dose levels subcutaneously once-weekly without titration. The extension phase includes dosing regimens that are less frequent than weekly.

    Drug: MET097

  • Placebo comparator
    Placebo

    Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.

    Drug: Placebo

Interventions

  • DrugMET097

    MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.

  • DrugPlacebo

    Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight at Week 28: Part A

    Analysis was performed using mixed model for repeated measures (MMRM) with treatment group, visit, and treatment by visit interaction, sex, and baseline body weight as fixed effects using unstructured covariance. The analysis excluded weight measurements after protocol specified intercurrent events (ICEs) including permanent treatment discontinuation, non-compliance to treatment and lifestyle change.

    Time frame: Baseline (last non-missing measurement prior to the first dose), Week 28

Secondary outcomes

  1. Percent Change From Baseline in Body Weight at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141 and 169: Part A

    Analysis was performed using MMRM with treatment group, visit, and treatment by visit interaction, sex, and baseline body weight as fixed effects using unstructured covariance excluding weight measurements after protocol specified intercurrent ICEs.

    Time frame: Baseline, Day 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141 and 169

  2. Number of Participants With Reduction in Body Weight Greater Than or Equal to (>=) 5 Percent (%) From Baseline at Week 28: Part A

    Time frame: Baseline, Week 28

  3. Number of Participants With Reduction in Body Weight >= 10 % From Baseline at Week 28: Part A

    Time frame: Baseline, Week 28

  4. Number of Participants With Reduction in Body Weight >= 15 % From Baseline at Week 28: Part A

    Time frame: Baseline, Week 28

  5. Change From Baseline in Body Weight at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197: Part A

    Time frame: Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197

  6. Change From Baseline in Body Mass Index (BMI) at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197: Part A

    BMI was derived from body weight in kilograms (kg) and height in meters (m), and it was calculated as weight divided by height\^2.

    Time frame: Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197

  7. Change From Baseline in Waist Circumference at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197: Part A

    Time frame: Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197

  8. Number of Participants With Gastrointestinal (GI) Adverse Event of Clinical Interest (AECI): Part A

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea.

    Time frame: From Day 1 of dosing up to 28 days after last dose for Part A

  9. Number of Participants With Treatment Related Gastrointestinal AECIs: Part A

    An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea. Treatment related gastrointestinal AECIs were GI AECIs that were related to study drug and relatedness was judged by investigator.

    Time frame: From Day 1 of dosing up to 28 days after last dose for Part A

  10. Number of Participants With Gastrointestinal AECI and Treatment Related AECIs by Severity: Part A

    An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea. Treatment related GI AECIs were GI AECIs that were related to study drug and relatedness was judged by investigator. Severity was assessed as mild: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; moderate: minimal, local or non-invasive intervention indicated, limiting age-appropriate instrumental activities of daily living and severe: medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living or life-threatening consequences, urgent intervention indicated or death related to an AE.

    Time frame: From Day 1 of dosing up to 28 days after last dose for Part A

  11. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs: Part A

    An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which does not necessarily have a causal relationship with the treatment. A TEAE was defined as any AE which on or after exposure to study treatment. Treatment related TEAEs were TEAEs that were related to study drug and relatedness was judged by investigator.

    Time frame: Up to Week 37

  12. Number of Participants With TEAEs and Treatment-Related TEAEs by Severity: Part A

    An AE was defined as any untoward medical occurrence in participant administered an investigational product and which does not necessarily have causal relationship with treatment. A TEAE was defined as any AE which on or after exposure to study treatment up to 28 days following the last dose. Treatment related TEAEs were TEAEs that were related to study drug and relatedness was judged by investigator. Severity: mild: asymptomatic/ mild symptoms, clinical/ diagnostic observations only, intervention not indicated; moderate: minimal, local/ non-invasive intervention indicated, limiting age-appropriate instrumental activities of daily living and severe: medically significant but not immediately life-threatening, hospitalization/ prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living/ life-threatening consequences, urgent intervention indicated/ death related to an AE.

    Time frame: Up to Week 37

  13. Number of Participants With Abnormal Clinically Significant Physical Examination: Part A

    The physical examination included examination of the following body systems (at minimum): head and neck (including complete thyroid exam), cardiovascular, respiratory, gastrointestinal, brief neurological, and general appearance. Clinical significance will be judged by investigator.

    Time frame: From Day 1 of dosing up to post treatment follow up for Part A

  14. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities: Part A

    Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes. Clinical significance will be judged by investigator.

    Time frame: From Day 1 of dosing up to post treatment follow up for Part A

  15. Number of Participants With Potential Clinically Significant Laboratory Values: Part A

    Laboratory parameters assessed included alanine aminotransferase (ALT) (units per liter \[U/L\]): greater than (\>) 1\*upper limit of normal (ULN), \>3\*ULN and \>5\*ULN; alkaline phosphatase (ALP) (U/L): \>2\*ULN; amylase (U/L): \>1\*ULN and \>3\*ULN; aspartate aminotransferase (AST): \>1\*ULN, \>3\*ULN and \>5\*ULN; estimated glomerular filtration rate (eGFR) (Ckd-Epi \[chronic kidney disease epidemiology collaboration\]) (milliliter per minute per 1.73m\^2): less than (\<) 60 mL/min/1.73m\^2, 60-90 mL/min/1.73m\^2 and \>90 mL/min/1.73m\^2; Lipase: \>1\*ULN and \>3\*ULN; neutrophils: \<1.5, \<0.5, 0.5 to \<1, 1 to \<1.5 and total bilirubin (milligrams per deciliter): \>2\* upper limit of normal (ULN). Potential clinical significance was judged by investigator.

    Time frame: From Day 1 of dosing up to post treatment follow up for Part A

  16. Number of Participants According to Columbia-Suicide Severity Rating Scale (C-SSRS) Categories: Part A

    The C-SSRS is a questionnaire designed for the assessment of suicidal ideation and behavior in adolescents and adults. C-SSRS were evaluated through category 1 to 10. Suicidal ideation score was defined as the maximum suicidal ideation category (i.e., category 1-5), with 0 assigned if no ideation was present. Suicidal ideation, defined as 'Yes' if 'Yes' was present in any of category 1-5 and suicidal behavior, defined as 'Yes' if 'Yes' was present in any of category 6-10 and suicidal ideation or behavior, defined as 'Yes' if 'Yes' was present in any of Category 1-10.

    Time frame: From Day 1 of dosing up to post treatment follow up for Part A

  17. Patient Health Questionnaire-9 (PHQ-9) Total Score: Part A

    The PHQ-9 is a questionnaire designed to monitor and measure the severity of depression in participants. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "0=not at all", "several days", "more than half the days" to "nearly every day". The total score ranges from 0 to 27 by adding score for each question (total points) where: Score 1-4: minimal depression; Score 5-9: Mild depression; Score 10-14: moderate depression; Score 15-19 moderately severe depression; Score 20-27: Severe depression. Higher score indicates greater severity of depression.

    Time frame: From Day 1 of dosing up to post treatment follow up for Part A

  18. Number of Participants With Anti Drug Antibodies (ADAs): Part A

    Number of participants with baseline, positive and negative ADAs are reported in this outcome measure.

    Time frame: From Day 1 of dosing up to post treatment follow up for Part A

  19. Minimum Observed Concentration (Cmin) of Berobenatide: Part A

    Time frame: From pre-dose on Day 1 up to 168 hours post-dose

  20. Area Under the Concentration Versus Time Curve During the Dosing Interval (AUC[0-tau]) of Berobenatide: Part A

    AUCtau was area under the concentration versus time curve during the dosing interval (tau), where, tau=168 hours.

    Time frame: From pre-dose on Day 1 up to 168 hours post-dose

  21. Maximum Observed Concentration (Cmax) of Berobenatide: Part A

    Cmax was observed directly from data.

    Time frame: From pre-dose on Day 1 up to 168 hours post-dose

  22. Time to Maximum Concentration (Tmax) of Berobenatide: Part A

    Time frame: From pre-dose on Day 1 up to 168 hours post-dose

  23. Plasma Concentration of Berobenatide: Part A

    Time frame: From pre-dose on Day 1 up to 168 hours post-dose

  24. Percent Change From Baseline in Body Weight: Part B

    Time frame: Baseline (last available measurement prior to first dose received in Part A), End of study

  25. Number of Participants With TEAEs: Part B

    An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which does not necessarily have a causal relationship with the treatment. A TEAE was defined as any AE which on or after exposure to study treatment up to 28 days following the last dose.

    Time frame: From Day 1 of dosing in Part B up to 28 days after last dose for Part B

07

Results

Posted Aug 28, 2026

Participant flow

The study consisted of 2 parts: Part A and optional Part B. Eligible participants who completed Week 28 (Day 197) assessments of Part A could enter Part B. The analysis for primary outcome measures are completed and results are reported based on primary analysis when all participants completed their Week 28 visit of Part A. Analysis for secondary outcome measures are still ongoing therefore, results for all secondary outcome measures and Part B of study will be reported upon study completion.

Participant flow — Overall Study
MilestonePart A: Placebo QWPart A: Berobenatide 0.4 mg QWPart A: Berobenatide 0.6 mg QWPart A: Berobenatide 0.9 mg QWPart A: Berobenatide 1.2 mg QW
Started4848484748
Completed00000
Not completed4848484748
Withdrew: Lost to follow-up00003
Withdrew: Participant unable or unwilling to comply with study visit schedule11000
Withdrew: Withdrawal by subject10010
Withdrew: Ongoing4647484645

Outcome measures

PrimaryPercent Change From Baseline in Body Weight at Week 28: Part A

Analysis was performed using mixed model for repeated measures (MMRM) with treatment group, visit, and treatment by visit interaction, sex, and baseline body weight as fixed effects using unstructured covariance. The analysis excluded weight measurements after protocol specified intercurrent events (ICEs) including permanent treatment discontinuation, non-compliance to treatment and lifestyle change.

Time frame:
Baseline (last non-missing measurement prior to the first dose), Week 28
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Body Weight at Week 28: Part A
Percent ChangePart A: Placebo QWPart A: Berobenatide 0.4 mg QWPart A: Berobenatide 0.6 mg QWPart A: Berobenatide 0.9 mg QWPart A: Berobenatide 1.2 mg QW
Percent Change From Baseline in Body Weight at Week 28: Part A1.67 ± 0.90-6.41 ± 0.89-8.36 ± 0.89-11.29 ± 0.90-12.45 ± 0.93
Statistical analysis
  • Part A: Placebo QW vs Part A: Berobenatide 0.4 mg QW · MMRM · p = <0.0001 · Ls mean difference: -8.09 · 95% CI -10.58 to -5.59
  • Part A: Placebo QW vs Part A: Berobenatide 0.6 mg QW · MMRM · p = <0.0001 · Ls mean difference: -10.03 · 95% CI -12.52 to -7.55
  • Part A: Placebo QW vs Part A: Berobenatide 0.9 mg QW · MMRM · p = <0.0001 · Ls mean difference: -12.96 · 95% CI -15.46 to -10.46
  • Part A: Placebo QW vs Part A: Berobenatide 1.2 mg QW · MMRM · p = <0.0001 · Ls mean difference: -14.13 · 95% CI -16.67 to -11.59
SecondaryPercent Change From Baseline in Body Weight at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141 and 169: Part A

Analysis was performed using MMRM with treatment group, visit, and treatment by visit interaction, sex, and baseline body weight as fixed effects using unstructured covariance excluding weight measurements after protocol specified intercurrent ICEs.

Time frame:
Baseline, Day 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141 and 169

Results for this outcome have not been posted.

SecondaryNumber of Participants With Reduction in Body Weight Greater Than or Equal to (>=) 5 Percent (%) From Baseline at Week 28: Part A
Time frame:
Baseline, Week 28

Results for this outcome have not been posted.

SecondaryNumber of Participants With Reduction in Body Weight >= 10 % From Baseline at Week 28: Part A
Time frame:
Baseline, Week 28

Results for this outcome have not been posted.

SecondaryNumber of Participants With Reduction in Body Weight >= 15 % From Baseline at Week 28: Part A
Time frame:
Baseline, Week 28

Results for this outcome have not been posted.

SecondaryChange From Baseline in Body Weight at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197: Part A
Time frame:
Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197

Results for this outcome have not been posted.

SecondaryChange From Baseline in Body Mass Index (BMI) at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197: Part A

BMI was derived from body weight in kilograms (kg) and height in meters (m), and it was calculated as weight divided by height\^2.

Time frame:
Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197

Results for this outcome have not been posted.

SecondaryChange From Baseline in Waist Circumference at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197: Part A
Time frame:
Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197

Results for this outcome have not been posted.

SecondaryNumber of Participants With Gastrointestinal (GI) Adverse Event of Clinical Interest (AECI): Part A

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea.

Time frame:
From Day 1 of dosing up to 28 days after last dose for Part A

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Related Gastrointestinal AECIs: Part A

An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea. Treatment related gastrointestinal AECIs were GI AECIs that were related to study drug and relatedness was judged by investigator.

Time frame:
From Day 1 of dosing up to 28 days after last dose for Part A

Results for this outcome have not been posted.

SecondaryNumber of Participants With Gastrointestinal AECI and Treatment Related AECIs by Severity: Part A

An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea. Treatment related GI AECIs were GI AECIs that were related to study drug and relatedness was judged by investigator. Severity was assessed as mild: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; moderate: minimal, local or non-invasive intervention indicated, limiting age-appropriate instrumental activities of daily living and severe: medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living or life-threatening consequences, urgent intervention indicated or death related to an AE.

Time frame:
From Day 1 of dosing up to 28 days after last dose for Part A

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs: Part A

An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which does not necessarily have a causal relationship with the treatment. A TEAE was defined as any AE which on or after exposure to study treatment. Treatment related TEAEs were TEAEs that were related to study drug and relatedness was judged by investigator.

Time frame:
Up to Week 37

Results for this outcome have not been posted.

SecondaryNumber of Participants With TEAEs and Treatment-Related TEAEs by Severity: Part A

An AE was defined as any untoward medical occurrence in participant administered an investigational product and which does not necessarily have causal relationship with treatment. A TEAE was defined as any AE which on or after exposure to study treatment up to 28 days following the last dose. Treatment related TEAEs were TEAEs that were related to study drug and relatedness was judged by investigator. Severity: mild: asymptomatic/ mild symptoms, clinical/ diagnostic observations only, intervention not indicated; moderate: minimal, local/ non-invasive intervention indicated, limiting age-appropriate instrumental activities of daily living and severe: medically significant but not immediately life-threatening, hospitalization/ prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living/ life-threatening consequences, urgent intervention indicated/ death related to an AE.

Time frame:
Up to Week 37

Results for this outcome have not been posted.

SecondaryNumber of Participants With Abnormal Clinically Significant Physical Examination: Part A

The physical examination included examination of the following body systems (at minimum): head and neck (including complete thyroid exam), cardiovascular, respiratory, gastrointestinal, brief neurological, and general appearance. Clinical significance will be judged by investigator.

Time frame:
From Day 1 of dosing up to post treatment follow up for Part A

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities: Part A

Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes. Clinical significance will be judged by investigator.

Time frame:
From Day 1 of dosing up to post treatment follow up for Part A

Results for this outcome have not been posted.

SecondaryNumber of Participants With Potential Clinically Significant Laboratory Values: Part A

Laboratory parameters assessed included alanine aminotransferase (ALT) (units per liter \[U/L\]): greater than (\>) 1\*upper limit of normal (ULN), \>3\*ULN and \>5\*ULN; alkaline phosphatase (ALP) (U/L): \>2\*ULN; amylase (U/L): \>1\*ULN and \>3\*ULN; aspartate aminotransferase (AST): \>1\*ULN, \>3\*ULN and \>5\*ULN; estimated glomerular filtration rate (eGFR) (Ckd-Epi \[chronic kidney disease epidemiology collaboration\]) (milliliter per minute per 1.73m\^2): less than (\<) 60 mL/min/1.73m\^2, 60-90 mL/min/1.73m\^2 and \>90 mL/min/1.73m\^2; Lipase: \>1\*ULN and \>3\*ULN; neutrophils: \<1.5, \<0.5, 0.5 to \<1, 1 to \<1.5 and total bilirubin (milligrams per deciliter): \>2\* upper limit of normal (ULN). Potential clinical significance was judged by investigator.

Time frame:
From Day 1 of dosing up to post treatment follow up for Part A

Results for this outcome have not been posted.

SecondaryNumber of Participants According to Columbia-Suicide Severity Rating Scale (C-SSRS) Categories: Part A

The C-SSRS is a questionnaire designed for the assessment of suicidal ideation and behavior in adolescents and adults. C-SSRS were evaluated through category 1 to 10. Suicidal ideation score was defined as the maximum suicidal ideation category (i.e., category 1-5), with 0 assigned if no ideation was present. Suicidal ideation, defined as 'Yes' if 'Yes' was present in any of category 1-5 and suicidal behavior, defined as 'Yes' if 'Yes' was present in any of category 6-10 and suicidal ideation or behavior, defined as 'Yes' if 'Yes' was present in any of Category 1-10.

Time frame:
From Day 1 of dosing up to post treatment follow up for Part A

Results for this outcome have not been posted.

SecondaryPatient Health Questionnaire-9 (PHQ-9) Total Score: Part A

The PHQ-9 is a questionnaire designed to monitor and measure the severity of depression in participants. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "0=not at all", "several days", "more than half the days" to "nearly every day". The total score ranges from 0 to 27 by adding score for each question (total points) where: Score 1-4: minimal depression; Score 5-9: Mild depression; Score 10-14: moderate depression; Score 15-19 moderately severe depression; Score 20-27: Severe depression. Higher score indicates greater severity of depression.

Time frame:
From Day 1 of dosing up to post treatment follow up for Part A

Results for this outcome have not been posted.

SecondaryNumber of Participants With Anti Drug Antibodies (ADAs): Part A

Number of participants with baseline, positive and negative ADAs are reported in this outcome measure.

Time frame:
From Day 1 of dosing up to post treatment follow up for Part A

Results for this outcome have not been posted.

SecondaryMinimum Observed Concentration (Cmin) of Berobenatide: Part A
Time frame:
From pre-dose on Day 1 up to 168 hours post-dose

Results for this outcome have not been posted.

SecondaryArea Under the Concentration Versus Time Curve During the Dosing Interval (AUC[0-tau]) of Berobenatide: Part A

AUCtau was area under the concentration versus time curve during the dosing interval (tau), where, tau=168 hours.

Time frame:
From pre-dose on Day 1 up to 168 hours post-dose

Results for this outcome have not been posted.

SecondaryMaximum Observed Concentration (Cmax) of Berobenatide: Part A

Cmax was observed directly from data.

Time frame:
From pre-dose on Day 1 up to 168 hours post-dose

Results for this outcome have not been posted.

SecondaryTime to Maximum Concentration (Tmax) of Berobenatide: Part A
Time frame:
From pre-dose on Day 1 up to 168 hours post-dose

Results for this outcome have not been posted.

SecondaryPlasma Concentration of Berobenatide: Part A
Time frame:
From pre-dose on Day 1 up to 168 hours post-dose

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Body Weight: Part B
Time frame:
Baseline (last available measurement prior to first dose received in Part A), End of study

Results for this outcome have not been posted.

SecondaryNumber of Participants With TEAEs: Part B

An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which does not necessarily have a causal relationship with the treatment. A TEAE was defined as any AE which on or after exposure to study treatment up to 28 days following the last dose.

Time frame:
From Day 1 of dosing in Part B up to 28 days after last dose for Part B

Results for this outcome have not been posted.

Adverse events

Collected over From Day 1 of dosing up to 28 days after last dose of study treatment (Week 32) for Part A. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo QW0/48 (0%)0/48 (0%)30/48 (62.5%)
Part A: Berobenatide 0.4 mg QW0/48 (0%)2/48 (4.2%)33/48 (68.8%)
Part A: Berobenatide 0.6 mg QW0/48 (0%)1/48 (2.1%)34/48 (70.8%)
Part A: Berobenatide 0.9 mg QW0/47 (0%)0/47 (0%)30/47 (63.8%)
Part A: Berobenatide 1.2 mg QW0/48 (0%)0/48 (0%)35/48 (72.9%)
Most frequent serious events
Most frequent serious events
EventPart A: Placebo QWPart A: Berobenatide 0.4 mg QWPart A: Berobenatide 0.6 mg QWPart A: Berobenatide 0.9 mg QWPart A: Berobenatide 1.2 mg QW
Obstructive pancreatitisGastrointestinal disorders0/481/480/480/470/48
Appendicitis perforatedInfections and infestations0/481/480/480/470/48
Alcohol poisoningInjury, poisoning and procedural complications0/480/481/480/470/48
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPart A: Placebo QWPart A: Berobenatide 0.4 mg QWPart A: Berobenatide 0.6 mg QWPart A: Berobenatide 0.9 mg QWPart A: Berobenatide 1.2 mg QW
NauseaGastrointestinal disorders13/4815/4817/4816/4724/48
VomitingGastrointestinal disorders6/4811/488/4813/4712/48
Upper respiratory tract infectionInfections and infestations9/4812/4810/484/4712/48
Decreased appetiteMetabolism and nutrition disorders7/4810/4812/4810/478/48
ConstipationGastrointestinal disorders8/4810/4811/4811/474/48
DiarrhoeaGastrointestinal disorders5/488/485/486/4711/48
HeadacheNervous system disorders7/4811/488/487/4710/48
DyspepsiaGastrointestinal disorders1/487/485/487/477/48
Abdominal distensionGastrointestinal disorders2/482/480/481/477/48
FatigueGeneral disorders3/487/482/486/476/48

Baseline characteristics

The full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(Years)Part A: Placebo QWPart A: Berobenatide 0.4 mg QWPart A: Berobenatide 0.6 mg QWPart A: Berobenatide 0.9 mg QWPart A: Berobenatide 1.2 mg QWTotal
Mean40.0 ± 11.4538.8 ± 11.3141.1 ± 12.4539.9 ± 12.6541.5 ± 10.7740.3 ± 11.69
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Placebo QWPart A: Berobenatide 0.4 mg QWPart A: Berobenatide 0.6 mg QWPart A: Berobenatide 0.9 mg QWPart A: Berobenatide 1.2 mg QWTotal
Female3332282731151
Male151620201788
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Placebo QWPart A: Berobenatide 0.4 mg QWPart A: Berobenatide 0.6 mg QWPart A: Berobenatide 0.9 mg QWPart A: Berobenatide 1.2 mg QWTotal
Hispanic or Latino3138323342176
Not Hispanic or Latino1691613660
Unknown or Not Reported110103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Placebo QWPart A: Berobenatide 0.4 mg QWPart A: Berobenatide 0.6 mg QWPart A: Berobenatide 0.9 mg QWPart A: Berobenatide 1.2 mg QWTotal
American Indian or Alaska Native001001
Asian1233110
Native Hawaiian or Other Pacific Islander000000
Black or African American132136438
White3240293541177
More than one race100001
Unknown or Not Reported1423212
08

Study locations

2 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Research Centers of America
    Hollywood, Florida 92801, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jul 2025, 8 months.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 8 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 2, 2024
StartActual
Oct 9, 2024
Primary completionActual
Jul 3, 2025
CompletionActual
Apr 30, 2026
Results first posted
Aug 28, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06712836
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Oct 9, 2024
Primary completion
Jul 3, 2025
Completion
Apr 30, 2026
Results posted
Aug 28, 2026
Last update
Aug 28, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berobenatide

Start the discussion